Compare BIO-TECHNE Corp (TECH) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Trade Desk Inc — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Trade Desk Inc trades at $13.9 (market cap $6.59B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| TECH | TTD | |
|---|---|---|
Market Cap | $11.34B | $6.59B |
Sector | Health | Technology |
52-Week High | $72.48 | $54.13 |
52-Week Low | $43.31 | $13.03 |
Enterprise Value | $11.36B | $5.54B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
The Trade Desk (TTD) trades at $14.02, down 2.84% amid bearish technical signals and recent earnings misses. The stock faces headwinds from slowing revenue growth (3% in Q2 2026) and a 15% workforce reduction announced in September 2026. Despite solid profitability margins (net margin 13.61%) and reasonable valuation (P/E 16.69), negative cash flow trends and competitive pressures weigh on sentiment. Technical indicators show resistance at $15 with support at $13-14, while analyst consensus remains mixed with a $14.07 price target.
Outlook: TTD's long-term ad-tech positioning and AI innovations (Kokai Zuma) offer growth potential, but near-term execution risks and macro ad demand softness pose challenges. Investors should monitor Q3 earnings and restructuring efficacy for catalysts. Risks include heightened competition and reliance on digital ad spending cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
